Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
Of the many different types
2024-12-11

Of the many different types of DNA lesions, DNA double strand breaks (DSBs) are amongst the most deleterious. It has been suggested that a single unrepaired DSB may be sufficient to induce cell death (Bennett et al., 1993), whereas misrepaired DSBs can result in loss of genetic information, potentia
-
Why do glutamate and glycine bind to the receptor in
2024-12-11

Why do glutamate and glycine bind to the 391 receptor in such different ways? Given the overall structural similarity between the GluN2A and GluN1 LBDs, one might conclude that the LBDs also bind ligands via similar processes. NMDA receptors with engineered disulfide linkages that lock the GluN1 lob
-
br Material and methods br Results
2024-12-11

Material and methods Results Discussion Didox was originally created asa cytostatic drug to inhibit cancer cell proliferation by antagonizing RNR [11]. When used to target highly proliferative cells, Didox has extensive activity in vitro and in vivo. It has also been employed in clinical st
-
glycine transporter No starting dose adjustment is needed
2024-12-11

No starting dose adjustment is needed for mild or moderate renal impairment and mild hepatic impairment (Child-Pugh A classification) though use in patients with severe hepatic impairment (Child-Pugh classification Class C, 10–15 points score) is not recommended.8, 9, 10, 13 Drug interaction & ad
-
br Acknowledgments and Disclosures br Alzheimer s disease as
2024-12-11

Acknowledgments and Disclosures Alzheimer's disease as a synaptic pathology Alzheimer's disease (AD) is a chronic neurodegenerative meclofenamate synthesis disorder and the most common cause of dementia in the elderly. Progressive depositions of amyloid plaques and neurofibrillary tangles tog
-
Ultracentrifugation of AD brain was reported to remove of A
2024-12-11

Ultracentrifugation of AD KT 5823 receptor was reported to remove >99.95% of Aβ, while only reducing seeding capacity by 70% (Langer et al., 2011). This suggests that the most potent seeding Aβ species are relatively small soluble oligomers rather than larger insoluble fibrils. It was also noted th
-
CC-4047 br Acknowledgments The authors thank Claudia Wittroc
2024-12-11

Acknowledgments The authors thank Claudia Wittrock for her excellent technical assistance. The work was supported by grants of the Deutsche Forschungsgemeinschaft (SFB974 TP B05) and of the Anton-Betz-Stiftung to N.K. A.M. is an associate member of the iBrain graduate school at the University of
-
AAT enzyme activity was readily detected
2024-12-11

AAT enzyme activity was readily detected in crude cell-free extracts obtained from berry tissues of all accessions but displayed different substrate selectivities (Fig. 2). Cell-free extracts derived from ‘Muscat Hamburg’ berries showed the highest AAT activity with all alcoholic substrates tested,
-
br Discussion In a series of linear mixed effects
2024-12-11

Discussion In a series of linear mixed effects models of longitudinal neuroanatomical change, we have identified genetic risk variants associated with an increase in Isotretinoin shape asymmetry in AD. The closest genes associated with significant SNPs include BIN1 (rs6733839), CD2AP (rs10948363
-
br Discussion The patient presented initially
2024-12-11

Discussion The patient presented initially only with parietal symptoms in the form of acalculia, visuo-spatial deficits, and visuo-perceptual deficits and dressing apraxia. He also had simultognosia as early symptoms. Later when the disease progressed he had recent memory deficits and language in
-
br Conflict of interest br Financial Support The
2024-12-11

Conflict of interest Financial Support The work is supported by research grants from Clinical Key Specialty Project of China and Clinical Medical Center of Suzhou, China (Szzx201502) and Jiangsu Province Special Program of Medical Science, China (BE2016672). Introduction Recently, function
-
AMPK is a serine threonine protein kinase composed
2024-12-11

AMPK is a serine/threonine protein kinase composed of a catalytic α subunit with the activating phosphorylation site (Thr172) and two regulatory subunits, β and γ. The two AMPK variants, α1 and α2, show different cellular localization in mammalian cells. AMPKα2 is detected in nuclear and non-nuclear
-
Our initial approach to identify hits was two pronged
2024-12-10

Our initial approach to identify hits was two-pronged and included a high-throughput screening (HTS) campaign of the OSI igf 1 inhibitor library as well as a virtual screening (VS) campaign, utilizing a publically available crystal structure of ACK1 (PDB code: ). A tolerance for protein flexibility
-
In order to investigate their effects
2024-12-10

In order to investigate their effects in vitro, therefore, we first used TE671 cells, which have provided a useful source of human AChR for in vitro and radioimmunoassay studies. We found no marked effect of either MuSK-MG or SNMG sera on AChR numbers or on AChR subunit expression. This appears to c
-
HT modulates cortical and hippocampal pyramidal cell functio
2024-12-10

5-HT modulates cortical and hippocampal pyramidal cell function in a very complex manner, since most 5-HT receptor subtypes (excitatory as well as inhibitory) are expressed on pyramidal BIBR 953 as well as GABAergic interneurons that exert inhibitory control over pyramidal cells (Leiser et al., 201
15479 records 51/1032 page Previous Next First page 上5页 5152535455 下5页 Last page